New options in treatment of advanced renal cancer
Mené sur 658 patients atteints d'un carcinome rénal à cellules claires de stade avancé ou métastatique, cet essai de phase III compare l'efficacité, du point de vue de la survie sans progression, et la toxicité du cabozantinib et de l'évérolimus
Together with axitinib, a selective VEGFR tyrosine kinase inhibitor, the mTOR inhibitor everolimus has been a standard of care for patients with advanced renal cell carcinoma progressing after first-line therapy with VEGFR tyrosine kinase inhibitors. Both drugs were assessed in randomised controlled trials with progression free survival as the primary endpoint. Axitinib was compared with sorafenib, a multikinase inhibitor not regarded as standard of care after previous VEGFR-inhibition, everolimus with placebo in a crossover design, including patients after one or multiple previous lines of treatment.
The Lancet Oncology 2016